Literature DB >> 20377475

Efficacy and safety of drugs for ulcerative colitis.

Laura Noddin Rosenberg1, Mark A Peppercorn.   

Abstract

IMPORTANCE OF THE FIELD: Ulcerative colitis (UC) is a chronic inflammatory disorder of the colon that carries considerable burden and morbidity for patients and presents a constant challenge in management for gastroenterologists. Continued advances in medical therapies provide a range of treatment options for patients, but with this is the need to balance the potential benefits of a particular medication with its side effect profile in both the short and the long term. AREAS COVERED IN THIS REVIEW: This article will review the current drugs used in the treatment of UC, including 5-amninosalicylates, antibiotics, steroids, immunomodulators and biologics, with particular attention to their indications, efficacy and toxicity profile. WHAT THE READER WILL GAIN: The reader will gain a comprehensive understanding of the various medical therapies used in the treatment of UC with focus on efficacy and toxicity profiles, allowing providers to choose appropriate medical therapies for their patients. TAKE HOME MESSAGE: The particular agent used depends upon the extent and severity of disease, with mild-to-moderate disease treated with conventional therapy including 5-amninosalicylates. Steroids are used in the short term to bring active disease into remission, and the more aggressive immunomodulators and biologics are reserved for more severe disease given their toxicity profiles.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20377475     DOI: 10.1517/14740331003639412

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  9 in total

1.  Pharmacokinetics, safety and tolerability of DA-6034, an anti-inflammatory agent, after single and multiple oral administrations in healthy volunteers.

Authors:  Jieon Lee; Kwang-Hee Shin; Jung-Ryul Kim; Kyoung Soo Lim; In-Jin Jang; Jae-Yong Chung
Journal:  Clin Drug Investig       Date:  2014-01       Impact factor: 2.859

2.  Bone marrow-derived mesenchymal stem cell transplantation ameliorates oxidative stress and restores intestinal mucosal permeability in chemically induced colitis in mice.

Authors:  Tao Sun; Guang-Zhou Gao; Rong-Fu Li; Xin Li; Da-Wei Li; Shan-Shan Wu; Anthony Et Yeo; Bo Jin
Journal:  Am J Transl Res       Date:  2015-05-15       Impact factor: 4.060

3.  Red wine polyphenol extract efficiently protects intestinal epithelial cells from inflammation via opposite modulation of JAK/STAT and Nrf2 pathways.

Authors:  Carla Nunes; Natércia Teixeira; Diana Serra; Víctor Freitas; Leonor Almeida; João Laranjinha
Journal:  Toxicol Res (Camb)       Date:  2015-10-05       Impact factor: 3.524

4.  Dandelion root extract protects NCM460 colonic cells and relieves experimental mouse colitis.

Authors:  Aiguo Ding; Xianhui Wen
Journal:  J Nat Med       Date:  2018-05-08       Impact factor: 2.343

5.  BTZO-15, an ARE-activator, ameliorates DSS- and TNBS-induced colitis in rats.

Authors:  Hiroshi Yukitake; Haruhide Kimura; Hirobumi Suzuki; Yasukazu Tajima; Yoshimi Sato; Toshihiro Imaeda; Masahiro Kajino; Masayuki Takizawa
Journal:  PLoS One       Date:  2011-08-10       Impact factor: 3.240

6.  3-(1H-Benzo[d]imidazol-6-yl)-5-(4-fluorophenyl)-1,2,4-oxadiazole (DDO7232), a Novel Potent Nrf2/ARE Inducer, Ameliorates DSS-Induced Murine Colitis and Protects NCM460 Cells against Oxidative Stress via ERK1/2 Phosphorylation.

Authors:  Li-Li Xu; Tian Liu; Lei Wang; Li Li; Yu-Feng Wu; Cui-Cui Li; Bin Di; Qi-Dong You; Zheng-Yu Jiang
Journal:  Oxid Med Cell Longev       Date:  2018-05-20       Impact factor: 6.543

7.  Huang-Lian-Jie-Du Decoction Ameliorates Acute Ulcerative Colitis in Mice via Regulating NF-κB and Nrf2 Signaling Pathways and Enhancing Intestinal Barrier Function.

Authors:  Ziwen Yuan; Lihong Yang; Xiaosong Zhang; Peng Ji; Yongli Hua; Yanming Wei
Journal:  Front Pharmacol       Date:  2019-11-21       Impact factor: 5.810

8.  Molecular mechanisms of Huanglian jiedu decoction on ulcerative colitis based on network pharmacology and molecular docking.

Authors:  Jing Yang; Chaotao Tang; Ruiri Jin; Bixia Liu; Peng Wang; Youxiang Chen; Chunyan Zeng
Journal:  Sci Rep       Date:  2022-04-01       Impact factor: 4.379

9.  An inhibitor of the Keap1-Nrf2 protein-protein interaction protects NCM460 colonic cells and alleviates experimental colitis.

Authors:  Meng-Chen Lu; Jian-Ai Ji; Yong-Lin Jiang; Zhi-Yun Chen; Zhen-Wei Yuan; Qi-Dong You; Zheng-Yu Jiang
Journal:  Sci Rep       Date:  2016-05-24       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.